Lupin launches Generic Aricept Tablets in the US

1st product launch from the GAVIS pipeline with 180 days exclusivity

id-100294534

Zolpidem Sublingual Tablets is indicated for use as needed for the treatment of insomnia

Pharma Major Lupin's US subsidiary has launched the first product from its GAVIS pipeline, Zolpidem Sublingual Tablets, 1.75 mg & 3.5 mg to market a generic equivalent of Purdue Pharma L.P's Intermezzo Sublingual Tablets, 1.75 mg & 3.5 mg, having received final approval from the United States Food & Drug Administration (FDA) earlier, as well as final clearance from the FTC with 180 days of exclusivity.

Zolpidem Sublingual Tablets, 1.75 mg & 3.5 mg are AB-rated generic equivalent of Purdue Pharma L.P's Intermezzo Sublingual Tablets, 1.75 mg & 3.5 mg and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.

Intermezzo had US sales of $9.46 million (IMS MAT December 2015).

 

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X